AF
OCUL icon

Amalgamated Financial’s Ocular Therapeutix OCUL Stock Holding History

Amalgamated Financial’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$62K Buy
+12,519
New +$69.4K ﹤0.01% 2320

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Amalgamated Financial's OCUL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Ocular Therapeutix (OCUL) in Q1 2022: 12,519 shares worth $62K. The stake represents ﹤0.01% of the portfolio and ranks #2320 among its holdings.

132 funds tracked by Wall St. Rank hold OCUL as of Q1 2022.

  • Amalgamated Financial held 12,519 shares of Ocular Therapeutix worth $62K as of Q1 2022.
  • Ocular Therapeutix was a new Amalgamated Financial position in Q1 2022.
  • Ocular Therapeutix made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2320 holding.
  • 132 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.